Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Rafael Holdings, Inc. (RFL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update NEWARK, NJ – October 29, 2026 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fi
How this was made
The 30-second read
Why it matters
The earnings release provides the first detailed financial picture for FY2026, highlighting a narrower loss and cash balance decline, which may affect financing strategies and stock volatility.
Market read
The report is a primary disclosure for a micro‑cap biotech, offering new data that could move the stock modestly in the short term.
What to watch
Potential upside from the priority‑review voucher and upcoming NDA decision could drive later upside.
Background
Rafael Holdings is a biotech focused on rare diseases, with its lead candidate remibetadex in a Phase 3 trial for Niemann‑Pick Disease Type C.
Ticker impact
Rafael Holdings reported its Q4 and full-year FY2026 financial results, including net loss, cash balance and R&D expenses.
likely modest pressure as investors weigh loss reduction against cash depletion and ongoing FDA uncertainty.
The numbers are new and directly affect valuation; however, the scale is limited for a micro‑cap biotech.
Market effects
Results may influence sentiment toward rare‑disease biotech peers awaiting FDA decisions.
Limited to U.S. biotech sector; no broader regional effect.
Low global impact beyond niche biotech investors.
Counterpoint
Despite loss reduction, cash runway is short; a short‑term sell could be justified.
Key entities
- companyRafael Holdings, Inc.
Biotech company reporting FY2026 results.
- subsidiaryCyclo Therapeutics
Unit contributing to increased R&D spend.
